Moxifloxacin Al

Moxifloxacin, the active ingredient in Moxifloxacin Al, is a fluoroquinolone presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and skin structure infections in adult patients.

GNH USA supplies Moxifloxacin Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. It is delivered through reliable logistics and comprehensive documentation.

Moxifloxacin is a fluoroquinolone antibiotic indicated for several bacterial respiratory and skin infections.

- Community‑acquired pneumonia: effective in eradicating susceptible Streptococcus pneumoniae and other typical pathogens. - Acute bacterial sinusitis: reduces bacterial load and alleviates sinus inflammation. - Acute bacterial exacerbation of chronic bronchitis: improves symptoms and shortens disease duration. - Skin and skin structure infections: treats infections caused by Staphylococcus aureus and other Gram‑positive organisms.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation - Severe allergic reaction (anaphylaxis)

Before prescribing Moxifloxacin, clinicians should consider several safety precautions.

- Assess renal function: adjust use in patients with severe impairment. - Monitor for tendon pain: discontinue if signs of tendinopathy appear. - Evaluate cardiac history: avoid in patients with known QT prolongation. - Review concomitant medications: avoid combinations that increase QT risk. - Check for hypersensitivity: do not use in individuals with known allergy to fluoroquinolones. - Store at below 25°C: keep in the original pack, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of the drug. - NSAIDs (e.g., ibuprofen): increase risk of central nervous system stimulation. - Warfarin: may enhance anticoagulant effect and raise bleeding risk.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., ciprofloxacin): may increase moxifloxacin plasma levels. - CYP3A4 inducers (e.g., rifampin): may lower drug concentration and reduce effectiveness. - Oral contraceptives: may experience reduced hormonal efficacy.